N ‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: an update and translational aspects

AbstractN‐acetyl‐seryl‐aspartyl‐lysyl‐proline (AcSDKP) is the endogenous peptide which has been confirmed to display excellent organ protective effects. Even though originally discovered as modulator of hemotopoietic stem cells, during recent two decades AcSDKP has been recognized as valuable anti‐ fibrotic peptide. The anti‐fibrotic mechanism of AcSDKP is not clear yet, we have established that AcSDKP could target endothelial mesenchymal transition (EndMT) program via the induction of endothelial fibroblast‐growth factor receptor signaling pathway. Also recent reports suggested the clinic al significance of AcSDKP. In this review, we aim to update recent advance of mechanistic action of AcSDKP and discussed about translational research aspect.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: REVIEW ARTICLE Source Type: research